AzTrials
AzTrials

CataractPhase 4IOLsNCT00576485

Spherical Aberration and Contrast Sensitivity in IOLs

A Phase 4 study testing Cataract surgery and intraocular lens implantation in people with Cataract and Signs and Symptoms, run by Federal University of Minas Gerais at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Purpose: To determine whether implantation of an intraocular lens (IOL) with a modified anterior aspheric surface results in reduced spherical aberration and improved contrast sensitivity after cataract surgery. Design: Prospective, comparative, interventional case series. Read more about this study

Who is it for?
Ages 45 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Cataract, Signs and Symptoms, Pseudophakia
What is being tested?
Cataract surgery and intraocular lens implantation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteBrazil
Study dates
Feb 2005to Dec 2007
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age-related cataract
  • No indication of existing ocular pathology
  • Unsatisfactory correction with glasses and
  • Less than 2.50 diopters (D) of topography cylinder.

Who cannot join

  • Previous ocular surgery
  • Central endothelial cell count less than 1800 cells/mm2
  • Glaucoma or intraocular pressure greater than 21 mmHg
  • Amblyopic eyes
  • Retinal abnormalities
  • Diabetes mellitus
  • Steroid or immunosuppressive treatment, and
  • Connective tissue diseases

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Federal University of Minas Gerais - Sao Geraldo Eye Hospital

    Belo Horizonte, Minas Gerais, 31270000

Other trials in Brazil

About this study

Official title: Spherical Aberration and Contrast Sensitivity in Eyes Implanted With Aspheric and Spherical Intraocular Lenses: Clinical Comparative Study

Purpose: To determine whether implantation of an intraocular lens (IOL) with a modified anterior aspheric surface results in reduced spherical aberration and improved contrast sensitivity after cataract surgery.

Design: Prospective, comparative, interventional case series.

Methods: In an intraindividual randomized prospective study of 25 patients with bilateral cataract, an IOL with a modified anterior surface (Tecnis Z9001, AMO- Group 1) was compared with biconvex lens with spherical surfaces (ClariFlex®, AMO- Group 2). Ocular aberrations for a 5.0 mm pupil and 6.0 mm pupil were measured with Hartmann-Shack aberrometer. Quality of vision was measured by visual acuity and contrast sensitivity under mesopic and photopic conditions. All patients were followed for 3 months.

Read the detailed description

With improvement in the quality of life and the resulting expansion of the elderly population, the prevalence of cataract cases will continue to rise. The population is on average older, and the environment has become more demanding for older people, who therefore need to regain excellent quality of vision. Advances in both IOL and phacoemulsification technology have enable cataract surgery to evolve from a procedure concerned with the safe removal of the cataract to a procedure refined to achieve the best possible postoperative refractive result.

Snellen visual acuity insufficiently describes the quality of the eye's optics before and after cataract surgery. 1-3 Multiple scientific studies have demonstrated that contrast sensitivity represents a robust indicator of functional vision. 4-7 The contrast sensitivity function, measured under varying conditions of luminance and glare, establishes the limits of visual perception across the spectrum of spatial frequencies.

Studies have demonstrated a nearly linear decline in image quality with age, suggesting a significant increase in the optical aberrations in the eye over time. 8-9 Advances in wavefront technology have opened a new door to the measurement of ocular aberrations. 9-10 Also, this technology allowed the development of a new type of IOL designed to compensate for the positive spherical aberration of the cornea, which is one of the most important aberrations contributing to visual deterioration of the pseudophakic eye. 11-14 Based on these findings, the approach to compensate for increasing spherical aberration in older eyes is to develop an IOL that introduces negative spherical aberration into the system. Such an IOL, the Tecnis Z9001® IOL (Model Z9001, Advanced Medical Optics, Santa Ana, CA), has been developed by AMO. This is a polysiloxane foldable 3-piece IOL, with anterior aspheric surface (negative spherical aberration) designed to decrease the total amount of ocular spherical aberration after cataract surgery.7

The purpose was to determine whether implantation of an intraocular lens (IOL) with a modified anterior aspheric surface results in reduced spherical aberration and improved contrast sensitivity after cataract surgery.

Patients and Methods

This double-blind prospective randomized study included patients with age-related cataract, no indication of existing ocular pathology, unsatisfactory correction with glasses and less than 2.50 diopters (D) of topography cylinder. Patients were offered the opportunity to be part of a clinical trial in which they would be allocated to have cataract surgery with implantation of aspherical or spherical IOL. Patients were randomized to receive a Tecnis Z9001 aspheric IOL in one eye and a ClariFlex spheric IOL in the fellow eye. To protect patient safety, after the first eye surgery, they were asked whether they wished to have the same lens type implanted in the second eye. Written informed consent was obtained from all patients before surgery and the study was approved by the local ethics committee. Exclusion criteria were previous ocular surgery, central endothelial cell count less than 1800 cells/mm2, glaucoma or intraocular pressure greater than 21 mmHg, amblyopic eyes, retinal abnormalities, diabetes mellitus, steroid or immunosuppressive treatment, and connective tissue diseases.

The selected lenses used in this study were the Tecnis Z9001® (Model Z9001, Advanced Medical Optics, Santa Ana, CA) and the ClariFlexTM (Advanced medical Optics, Santa Ana, CA) (Table 1). Eyes in Group 1 (n=25) received the Tecnis Z9001® (Model Z9001) and eyes in Group 2 (n=25) received the ClariFlexTM (Table 1).

The Holladay formula was used to calculate the IOL power when there was a short axial length (< 22.0 mm) and the SRK/T formula was used when there was an average axial length (≥ 22.0 mm). The A-constant used was 119.1 for the Tecnis Z9001 IOL and 118.0 for the ClariFlex IOL. Axial length was measured with the IOL Master (Carl Zeiss Meditec AG), and the targeted postoperative refractive error was 0.0.

Preoperative and postoperative evaluation included uncorrected distance visual acuity (UCDVA), best corrected visual acuity (BCVA), spherical equivalent (SE), slitlamp biomicroscopy, applanation tonometry, fundus examination, B-scan biometry, specular microscope and corneal topography. Topography was performed in all patients using the EyeSys unit (Version 3.03; EyeSys Technologies, Houston, Texas). The corneal endothelial cell count was also recorded for all eyes (noncontact specular microscope, NonCon Robo, Konan). The visual acuity measurements were recorded with logMAR UCDVA and BCVA. Clinical data were collected preoperatively and 1 and 3 months postoperatively for each eye.

All patients were operated in the same fashion by the same surgeon. All patients received topical anesthesia by lidocaine 2% gel before surgery. A 2.75 mm self-sealing clear cornea incision was made on the temporal side. Viscoelastic solution of sodium hyaluronate 3% and chondroitin sulfate 4% (Viscoat®) was used to reform and stabilize the surgical planes and protect the endothelium. A 5.00 to 5.25 mm continuous curvilinear capsulorhexis was initially performed with a 26-gauge needle and completed with forceps. The nucleous was removed without intraoperative complications such as posterior capsule rupture. Phacoemulsification was performed using the Infinite (Alcon Surgical) or Sovereign machine (Allergan Surgical). All IOLs were inserted in the capsular bag with the injector system. The viscoelastic material was completely removed at the end of the procedure. No sutures were used in any case. After 1 week the patient had the fellow eye operated. Postoperative medication included moxifloxacin (Vigamox®) or gatifloxacin (Zymar®) 4 times a day for 2 weeks, 0.1% diclofenaco sodium (Voltaren) 3 times a day for 4 weeks and steroid (Predfort) eyedrops 4 times a day for 6 weeks. Postoperative follow-up was 1 day, 1 and 3 months.

Postoperative evaluations were performed at 1 day, 1 month, and 3 months. At 1 month and 3 months, visual acuity, refraction, contrast sensitivity (CSV-1000 HGT, Vector Vision Inc.), and wavefront analysis with the Zywave aberrometer (Bauch \& Lomb, Rochester, New York) were performed.

Contrast sensitivity was measured using the CSV-1000 HGT testing instrument (Vector Vision Inc.), which presents a translucent chart divided into 4 cycles with spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). The background illumination of the translucent chart does not depend on room lighting; rather, it is provided by a fluorescent luminance source of the instrument and is automatically calibrated to 85 candelas/m2. All measurements were obtained under mesopic (5 cd/m2) and photopic (85 cd/m2) conditions. Each cycle contains 17 round patches that are 1.5 inches in diameter. The first patch has a high-contrast grating and presents the sample. The test patches are arranged in 2 rows with 8 levels of contrast. The levels decreased from left to right along the row in a logarithmic fashion in 0.17 log units for steps 1 through 3 and 0.15 log units for steps 3 through 8. The examinations were performed unilaterally at a distance of 2.5 m with best corrected visual acuity (BCVA) and an undilated pupil. All measurements were conducted under the same conditions by an examiner who was unaware of the type of IOL implanted.

Wavefront analysis was performed by the Zywave aberrometer. The Zywave aberrometer uses the Hartmann-Shack method of analysis of the outgoing wavefront that measures up to fifth-order Zernike aberrations, including coma, trefoil, and spherical aberrations.

For statistical analysis of visual acuity, logarithm of minimum angle of resolution (logMAR) acuity values were used. Similarly, the recorded contrast sensitivity values were transformed into log values as described by Vector Vision. All data analyses were performed using SPSSX statistical programs (SPSS Inc, Chicago, IL). The 2 IOLs were compared between eyes intraindividually. The analysis was based on a non-normal distribution of the data. The nonparametric Mann-Whitney U test was used to compare data between the 2 IOL groups. A P value less than 0.05 was considered statistically significant.

Being tested
Cataract surgery and intraocular lens implantation
Keywords
Cataract, Intraocular lens, Spherical aberration, Contrast sensitivity
Medical subject headings
Cataract, Signs and Symptoms, Pseudophakia, Lens Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cataract surgery and intraocular lens implantationProcedure or surgery

    Cataract surgery and implantation of an intraocular lens

Study groups in NCT00576485
Study groupRoleWhat they receive
1ExperimentalCataract surgery and implantation of a spherical intraocular lens
Receives: Procedure: Cataract surgery and intraocular lens implantation
2ExperimentalCataract surgery and implantation of a spherical intraocular lens
Receives: Procedure: Cataract surgery and intraocular lens implantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine whether implantation of an intraocular lens (IOL) with a modified anterior aspheric surface results in reduced spherical aberration and improved contrast sensitivity after cataract surgery

    Measured: within the first 30 days of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2007 (estimated)
  2. Study startFeb 2005
  3. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00576485
Sponsor's protocol ID
490/06
Other IDs
ETIC490/06
Acronym
IOLs
Status last verified
Dec 2007
First submitted
18 Dec 2007
Last updated
20 Oct 2008
Results posted
No
Data monitoring committee
Yes

Publications

  • Tzelikis PF, Akaishi L, Trindade FC, Boteon JE. Spherical aberration and contrast sensitivity in eyes implanted with aspheric and spherical intraocular lenses: a comparative study. Am J Ophthalmol. 2008 May;145(5):827-33. doi: 10.1016/j.ajo.2007.12.023. Epub 2008 Mar 4.

    PubMed 18291345

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Cataract surgery and intraocular lens implantation in people with Cataract and Signs and Symptoms, run by Federal University of Minas Gerais at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Oct 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine whether implantation of an intraocular lens (IOL) with a modified anterior aspheric surface results in reduced spherical aberration and improved contrast sensitivity after cataract surgery (time frame: within the first 30 days of surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00576485, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2008.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in